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In the vascular system, nitric oxide is generated by
endothelial NO synthase (eNOS). NO has pleiotropic ef-
fects, most of which are believed to be atheroprotective.
Therefore, it has been argued that patients suffering
from cardiovascular disease could benefit from an in-
crease in eNOS activity. However, increased NO produc-
tion can cause oxidative damage, cell toxicity, and apo-
ptosis and hence could be atherogenic rather than
beneficial. To study the in vivo effects of increased eNOS
activity, we created transgenic mice overexpressing hu-
man eNOS. Aortic blood pressure was 20 mm Hg lower
in the transgenic mice compared with control mice be-
cause of lower systemic vascular resistance. The effects
of eNOS overexpression on diet-induced atherosclerosis
were studied in apolipoprotein E-deficient mice. Eleva-
tion of eNOS activity decreased blood pressure (20 mm
Hg) and plasma levels of cholesterol (17%), resulting in
a reduction in atherosclerotic lesions by 40%. We con-
clude that an increase in eNOS activity is beneficial and
provides protection against atherosclerosis.
Endothelial nitric oxide synthase (eNOS)1 plays an impor-
tant role in the regulation of vascular tone, vascular biology,
and hemostasis. For example, NO produced by eNOS causes
vasodilation. Thus, eNOS knockout mice are hypertensive (1),
whereas eNOS transgenic mice have hypotension (2). In addi-
tion, NO reduces the activation and aggregation of platelets (3,
4), attenuates adhesion of leukocytes to the endothelium (5–7),
reduces the permeability of the endothelium, and inhibits pro-
liferation and migration of vascular smooth muscle cells (8).
Impaired activity of eNOS is associated with endothelial cell
dysfunction (9). For these reasons eNOS has been proposed to
modulate atherosclerotic disease (10–12). Indeed, impairment
or deficiency of eNOS gives rise to accelerated atherosclerosis
in animal models (10, 12–14), indicating that physiological
levels of eNOS are anti-atherogenic. This suggests that pa-
tients at increased risk of atherosclerotic vascular disease
could possibly benefit from an increase of eNOS activity by
pharmacological means or (local) gene therapy. However,
eNOS-derived NO also has detrimental effects (15), such as the
generation of superoxides (16), making it difficult to predict
whether increased eNOS activity is beneficial or harmful (17).
To determine whether increased eNOS activity may be benefi-
cial, we created transgenic mice that express the human eNOS
gene. These mice were crossbred to apolipoprotein E-deficient
(apoE0) mice in order to evaluate the effects of a constitu-
tive increase in eNOS activity on the development of
atherosclerosis.
EXPERIMENTAL PROCEDURES
Mice
A DNA fragment containing the human eNOS gene was isolated from
a homemade human genomic cosmid library (18) using eNOS cDNA
(kindly donated by Dr. S. Janssens, Leuven, Belgium; Ref. 19) as a
probe. In addition, the DNA fragment contained 6 kb of 5-natural
flanking sequence, including the native eNOS promoter, and 3 kb of
3-sequence to the gene. Vector sequences were removed by restriction
endonucleases. A solution of 1–2 g/ml DNA was used for microinjec-
tion of fertilized oocytes from FVB donor mice and transplanted into the
oviducts of pseudopregnant B10  CBA mice. Founder mice and off-
spring were genotyped by PCR on DNA isolated from tail biopsies.
Primers used were sense, 5-GTCCTGCAGACCGTGCAGC-3, and an-
tisense, 5-GGCTGTTGGTGTCTGAGCCG-3. Mice were backcrossed to
C57Bl6 for at least five generations (96% C57Bl6). All eNOS trans-
genic mice were hemizygous. ApoE0 mice were obtained from The
Jackson Laboratory, Bar Harbor, ME. Male mice were used in all
experiments. All animal experiments were performed in compliance
with institutional (Erasmus Medical Center, Rotterdam, The Nether-
lands) and national (Ministry of Health, Welfare, and Sport, The
Hague, The Netherlands) guidelines.
Western Blotting and Immunohistochemistry
Aortas were collected and homogenized in 50 mM Tris-HCl, pH 7.4,
containing 1 mM EDTA, 0.25 M sucrose, and 20 mM CHAPS. Western
blotting was performed as described previously (20). 25 g of protein
(BCA protein assay kit; Pierce) was applied to each lane. Anti-eNOS
was obtained from Santa Cruz Biotechnology Inc., Santa Cruz, CA. This
antibody was also used for immunohistochemistry experiments, which
were performed according to Bakker et al. (21).
Hemodynamic Measurements
Baseline Blood Pressure Measurements—Mice were weighed, anes-
thetized with ketamine (100 mg/kg intraperiteoneal) and xylazine (20
mg/kg intraperitoneal), intubated, and ventilated with a mixture of O2
and N2 (1/2 v/v) with a pressure-controlled ventilator (Servo ventilator
900C, Siemens-Elema, Sweden). The ventilation rate was set at 100
strokes/min with a peak inspiration pressure of 18 cm H2O and a
positive end expiration pressure of 6 cm H2O. After intubation the mice
were placed on a heating pad to maintain body temperature at 37 °C,
and a polyethylene catheter (PE 10) was inserted into the right carotid
artery and advanced into the aortic arch for the measurement of aortic
pressure. In the first part of the study we used 12 eNOS-Tg2 and 5
eNOS-Tg3 mice for screening of eNOS expression and compared them
to 33 wild type mice. Ten minutes after a second intraperitoneal bolus
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of anesthetics (100 mg/kg ketamine and 20 mg/kg xylazine), baseline
blood pressure recordings were obtained.
Effect of L-NAME on Systemic Vascular Resistance—Subsequently,
we chose the eNOS-Tg2 line to determine whether the lower aortic
blood pressure was the result of a NO-mediated decrease in systemic
vascular resistance. For this purpose, in 17 eNOS-Tg2 mice and 17 wild
type mice a polyethylene catheter (PE 10) was inserted into the right
carotid artery and advanced into the aortic arch for the measurement of
aortic pressure, while another PE 10 catheter was introduced into the
right external jugular vein and advanced into the superior caval vein for
infusion of L-NAME. After thoracotomy through the second right inter-
costal space, the ascending aorta was exposed and a transit-time flow
probe (ID 1.5 mm; T206; Transonics Systems Inc.) was placed around
the aorta for measuring aorta flow. Ten minutes after a second intra-
peritoneal bolus of 100 mg/kg ketamine and 20 mg/kg xylazine, baseline
recordings were obtained. A continuous 10-min intravenous infusion of
L-NAME (100 mg/kg) was started; 10 min after completion of the infu-
sion, measurements were repeated.
Effects of Dietary Suppletion of L-Arginine on Baseline Hemodynam-
ics—In the eNOS-Tg2 line we studied whether L-arginine deficiency
contributed to the modest effects of eNOS overexpression on systemic
vascular resistance. For this purpose, in six eNOS-Tg2 male mice and
seven wild type male mice, L-arginine was supplemented in their drink-
ing water (2.5% w/v). One week later, animals were instrumented as
described above, and hemodynamic measurements were performed un-
der baseline conditions.
Data Analysis—Hemodynamic data were recorded and digitized us-
ing an online 4-channel data acquisition program (ATCODAS, Dataq
Instruments, Akron, OH), for later analysis with a program written in
MatLab (Mathworks Inc, Natick, MA). Fifteen consecutive beats were
selected for determination of heart rate, aortic pressure, and aorta blood
flow.
eNOS Activity Assay
Aortas were collected and homogenized in 50 mM Tris-HCl, pH 7.4,
containing 1 mM EDTA, 0.25 M sucrose, and 20 mM CHAPS. eNOS
activity assays were performed by measuring L-arginine to L-citrulline
conversion using a nitric oxide synthase assay kit (Calbiochem, La
Jolla, CA; catalogue no. 482700) according to the manufacturer’s in-
structions. Protein content was measured by the BCA protein assay kit
(Pierce).
Lipid Measurements
Blood was collected via orbital puncture after an overnight fasting
period. Plasma was frozen freshly or subjected to ultracentrifugation in
a Beckman 42.2 Ti rotor (42,000 rpm, 3 h, 12 °C) at d  1.063 g/ml.
Tubes were sliced, and two fractions were collected: very low density
lipoprotein (VLDL) low density lipoprotein (LDL), d1.063 g/ml; and
high density lipoprotein (HDL), d 1.063 g/ml. Cholesterol was meas-
ured with the F-chol kit (Roche Molecular Biochemicals) after hydrol-
ysis of cholesteryl esters with cholesterol esterase from Candida cylin-
dracea (Roche Molecular Biochemicals).
Atherosclerosis
Atherosclerosis experiments were performed in age- and sex-
matched mice. Male mice of 8 weeks were fed a Western type diet
containing 15% (w/w) cacoa butter and 0.25% (w/w) cholesterol (diet W,
Hope Farms, Woerden, The Netherlands) for 6 weeks, which leads to
appreciable atherosclerosis (22–24). Animals were anesthetized using
isoflurane, and in situ fixation was performed via the left ventricle of
the heart using phosphate-buffered formalin (4%, v/v). A Sony digital
camera was used to obtain images of sections of the aortic root. These
were analyzed by Scion Image processing and analyzing software
(available from www.scioncorp.com). Atherosclerosis was quantified in
five sections per mouse with 80-m intervals using the method of
Paigen et al. (25).
Data Analysis
Analysis of data was performed using two- or one-way analysis of
variance followed by the Scheffe´ test, as appropriate. Statistical signif-
icance was accepted when p 0.05 (two-tailed). Data are presented as
mean  S.E.
RESULTS AND DISCUSSION
For the generation of eNOS transgenic mice, we used a DNA
fragment that comprised the complete human eNOS genomic
sequence, including all exons and introns as well its natural
flanking sequences. Therefore, our mice are different from
those described by Ohashi et al. (2), which overexpressed bo-
vine eNOS cDNA, driven by the murine preproendothelin-1
promoter. Our approach was chosen to preserve the natural
regulation of the gene and to prevent ectopic expression. For
example, the endothelium enhancer element that is located 4.9
kilobases upstream from the transcription start site of the
eNOS gene (26) is included in this construct. By using this
construct we mimic the human situation in terms of regulation
and tissue distribution of eNOS as much as possible.
Two independent lines with appreciable overexpression of
the transgene, as measured by RT-PCR (not shown), were
selected and arbitrarily designated eNOStg2 and eNOStg3.
Production of human eNOS protein was demonstrated by West-
ern blotting of aorta homogenates (Fig. 1A). Subsequently,
eNOS activity in aortas from control (wild type) and eNOS
overexpressing mice was measured, using the L-arginine to
L-citrulline conversion assay (27). In aorta, the level of active
eNOS enzyme was 10-fold increased in eNOStg2 mice and
7.5-fold in eNOStg3 mice when compared with wild type ani-
mals (Fig. 1B). Expression of human eNOS was also investi-
gated by immunohistochemistry. There was no human eNOS
staining of aortas of wild type mice, whereas the endothelial
layer of the aorta was clearly stained in both human eNOS
transgenic lines (Fig. 1C).
The expression pattern of the human eNOS transgene was
investigated by immunohistochemistry in heart (Fig. 2A), liver
(Fig. 2B), kidney (Fig. 2C), adrenal (Fig. 2D), and testis (Fig.
2E). Sections from wild type controls show virtually no immu-
nostaining (not shown). The lining of the larger vessels is
clearly stained (Fig. 2, A, D, and E). Staining of capillaries is
visible in the heart between the cardiomyocytes. Immunoreac-
tivity is observed in the sinusoids in the liver and in the kidney
in the peritubular capillaries as well as in the capillaries from
the glomeruli. In the adrenal, the cortical capillaries as well as
medullary capillary sinusoids and veins are stained. In the
testis, only blood vessels between the seminiferous tubules are
stained. No appreciable immunoreactivity is perceptible in the
parenchyma cells of any of these organs. Similar results were
found with sections from eNOStg3 mice (not shown).
Our results show that the genomic sequences included in the
DNA fragment we used are sufficient for expression in endo-
thelial cells. Although eNOS activity is tightly regulated at the
post-translational level (28, 29), there is also extensive regula-
tion at the transcriptional level (30, 31). The present study
shows that our construct results in high level expression of
human eNOS that is not prevented by a feedback mechanism.
To study the effect of increased eNOS activity on blood pres-
sure and vascular tone, we performed hemodynamic studies
(32). Heart rates were similar for wild type controls and eNOS
transgenic lines, although the eNOS transgenic lines each ex-
hibited a 20–25-mm Hg lower mean aortic blood pressure com-
pared with littermate controls (Fig. 3A). Subsequent hemody-
namic studies were performed in eNOStg2, the transgenic
mouse line with the highest expression. These experiments
showed that the lower aortic blood pressure was the result of a
30% lower systemic vascular resistance, because mean aortic
blood flow and heart rate were similar in both groups (Fig. 3B).
Subsequent infusion of the NOS inhibitor, L-NAME, increased
systemic vascular resistance and abolished the difference be-
tween control and eNOStg2 mice. We therefore conclude that
the lower basal systemic vascular resistance in eNOStg2 mice
is the result of increased NO production (Fig. 3B). This is
corroborated by the significantly larger increase in blood pres-
sure in response to L-NAME in the transgenic mice. Suppletion
of L-arginine had no effect on the already lower mean aortic
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blood pressure and heart rate in the transgenic mice (Fig. 3C).
We therefore also conclude that the blood pressure-lowering
effect of eNOS overexpression was not limited by a shortage of
substrate.
The present study shows that the lower blood pressure as-
sociated with eNOS overexpression (as reported in Ref. 2) is the
result of a lower systemic vascular resistance. Thus eNOS
activity was not only increased in the larger blood vessels but
also in the microcirculation. Although eNOStg2 and -3 mice
showed a slight variation in eNOS activity (Fig. 1B), the degree
FIG. 1. Expression of eNOS in transgenic mice. A, Western blot
analysis of aortas from control (wild type littermates), eNOStg2, or -3
mice. 25 g of homogenate was applied per lane. The blot was probed
with antihuman eNOS antibody. A single protein band of the expected
molecular size (130 kDa) was detected. B, eNOS activity was meas-
ured in aortas from control (Wt), eNOStg2 (Tg2), or -3 (Tg3) mice by the
L-arginine to L-citrulline conversion assay using a nitric oxide synthase
assay kit (Calbiochem). Activity is expressed as percentage of the ac-
tivity in controls, which was 1.56  0.31 pmol/g/min. Each value
represents the mean  S.E. of three animals. One of three experiments
is shown. *, p 0.05 versus controls; †, p 0.05 versus eNOStg2 mice
(analysis of variance followed by the Scheffe´ test). C, immunohisto-
chemistry on aortas from control, eNOStg2, or -3 mice. Aortas were
collected after in situ fixation. Paraffin sections were incubated with
antihuman eNOS antibody and a peroxidase-conjugated secondary an-
tibody. Original magnification, 630.
FIG. 2. Expression pattern of human eNOS in transgenic mice.
Organs from eNOStg2 mice were collected after in situ fixation. Paraf-
fin sections were incubated with antihuman eNOS antibody and a
peroxidase-conjugated secondary antibody. A, heart. B, liver. C, kidney.
D, adrenal. E, testis tissue. Arrowheads indicate representative immu-
noreactive capillaries; arrows indicate larger blood vessels. Original
magnification, 400.
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to which blood pressure was lowered was not different. This
suggests that another rate-limiting factor or one or more com-
pensatory mechanisms prevented a further decrease in blood
pressure in the eNOStg2 mice.
To study whether increased expression of eNOS protects the
mice against the development of diet-induced atherosclerosis,
eNOS transgenic mice were cross-bred to apoE0 mice, which
represent a well known mouse model for studying atheroscle-
rosis (33, 34). The animals were fed a Western type diet for 6
weeks. As shown in Fig. 4A, overexpression of eNOS also
caused a decrease in systemic blood pressure under these con-
ditions, although heart rates were similar. Plasma cholesterol
levels were measured before the start of the atherogenic diet
(i.e. on normal chow diet) and at the end of the experiment
(Table I). Both eNOS transgenic lines showed a decrease in
plasma cholesterol of 15% when compared with apoE0 mice
when fed a normal chow diet. As expected, the Western diet
resulted in a dramatic increase (3-fold) in plasma cholesterol
levels, whereas the total cholesterol concentration remained
16% lower in the eNOS transgenic animals when compared
with apoE0 controls. This difference was because of variations
in VLDL and LDL, which contain the bulk of the plasma
cholesterol under these conditions: HDL-cholesterol concentra-
tion in plasma was 0.4 mM and did not differ between the
groups (Table I). These findings indicate that elevated eNOS
activity results in a slightly more favorable (i.e. less athero-
FIG. 3. Hemodynamic measurements. A, mean aortic pressure
and heart rate were measured in anesthetized control (wild type litter-
mates, Wt), eNOStg2 (Tg2), or -3 (Tg3) mice. B, mean aortic pressure,
heart rate, mean aortic blood flow, and systemic vascular resistance
were analyzed in Wt or eNOStg2 mice before and following infusion of
L-NAME. C, mean aortic pressure and heart rate were measured in
anesthetized Wt or Tg2 mice following 1 week of drinking water with or
without L-arginine supplementation (L-Arg, 2.5% w/v). Each value rep-
resents the mean  S.E. of  five animals. *, p 0.05 versus Wt. †, p
0.05 versus baseline (before infusion of L-NAME). ‡, p0.05 versus Wt
after infusion of L-NAME (analysis of variance followed by the Scheffe´
test).
FIG. 4. Analysis of eNOS transgenic/apoE-deficient mice. A,
mean aortic pressure and heart rate were measured in anesthetized
apoE0, n 15; apoE0/eNOStg2, n 8; or apoE0/eNOStg3, n 8 mice.
B, representative photomicrographs of hematoxylin and eosin-stained
paraffin sections with lesion areas in the aortic valves (arrowheads).
Original magnification, 25. C, lesion area in the aortic root of apoE0;
n  32; apoE0/eNOStg2, n  22; or apoE0/eNOStg3, n  19 mice.
Areas were measured in five sections with 80-m intervals and ex-
pressed as m2 per section per animal.
TABLE I
Plasma lipid and lipoprotein analysis
Total cholesterol concentrations in plasma from apoE-deficient con-
trol (apoE0), apoE0/eNOStg2, or apoE0/eNOStg3 mice after feeding a
normal chow diet or an atherogenic diet. Cholesterol concentrations
were determined by enzymatic methods. VLDL  LDL and HDL frac-
tions were isolated by ultracentrifugation. TC, total cholesterol (mM);
VLDL  LDL, cholesterol in VLDL and LDL (mM); HDL, cholesterol in
HDL (mM).
n Chow TC
Atherogenic diet
TC VLDL  LDL HDL
apoE0 32 10.9  0.3 28.4  0.9 27.3  0.8 0.4  0.02
apoE0/eNOStg2 22 9.2  0.4a 23.3  1.1a 21.9  1.1b 0.4  0.02
apoE0/eNOStg3 19 9.0  0.2b 24.4  1.1c 24.3  1.0c 0.4  0.02
a p  0.01.
b p  0.001.
c p  0.05.
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genic) lipoprotein profile, because VLDL and LDL contain the
atherogenic portion of plasma cholesterol (35), whereas HDL is
protective against the development of atherosclerosis (36, 37).
To study the effect of eNOS overexpression on atherosclero-
sis, the atherosclerotic lesion areas in the aortic roots were
measured. Fig. 4B shows representative examples of histolog-
ical sections. Compared with apoE0 mice, we observed a de-
crease in atherosclerosis in both lines of eNOS transgenic mice
studied (Fig. 4C).
Several studies have described a relation between plasma
cholesterol and eNOS activity (38–40). However, these inves-
tigations exclusively focused on the effects of changes in
plasma cholesterol levels on eNOS activity. Hypercholesterol-
emia is associated with decreased eNOS activity, probably via
an interaction of oxidized LDL with caveolae, the plasma mem-
brane domains in which eNOS resides (41). Cholesterol synthe-
sis inhibitors (statins) have been reported to increase eNOS
activity in addition to their cholesterol lowering effects, but
these actions appear to be independent (38). In the present
study we observed that the level of eNOS expression affects the
level of plasma cholesterol: plasma levels of cholesterol were
about 15% lower in eNOStg/apoE0 mice as compared with
apoE0 controls. A similar difference in plasma cholesterol lev-
els was found after feeding the mice a Western type diet for 6
weeks, indicating that eNOS overexpression alleviates diet-
induced hypercholesterolemia. This effect is not caused by ec-
topic expression in organs involved in lipid metabolism, e.g. the
liver, because the expression pattern is restricted to endothe-
lial cells in all organs that were examined (Fig. 2). Recently it
was shown that hypercholesterolemia in mice results in CD36-
mediated cholesterol depletion of caveolae, followed by trans-
location of eNOS from caveolae and subsequent inactivation of
the enzyme (42). Thus, eNOS activity is directly related to the
cholesterol content of caveolae. Possibly, the moderate decrease
in plasma cholesterol that we observed in our eNOS transgenic
mice is caused by a recruitment of plasma cholesterol by the
endothelial cells in order to handle the increased level of eNOS
protein. This small decrease in plasma cholesterol likely con-
tributed, at least in part, to the observed lower susceptibility to
diet-induced atherosclerosis.
Although it has been proposed that elevation of eNOS activity
would attenuate atherosclerosis (11), serious doubts have also
been expressed as to whether an increase in eNOS activity in vivo
would have beneficial effects, because high levels of NO (e.g. as
produced by inducible NO synthase) have been implicated in cell
toxicity and apoptosis (15, 43). During the preparation of our
report, Ozaki et al. (44) reported the unexpected observation that
relatively modest overexpression of eNOS resulted in increased
atherosclerosis. Based on our findings, we conclude that this
observation cannot be generalized, taking into account the fol-
lowing considerations. First, because enzyme activity is  1.5-
fold increased, the level of eNOS overexpression in the mice used
by Ozaki et al. is relatively low when compared with the much
higher NO production levels by activated inducible NO synthase.
A 1.5-fold increase is also rather low in terms of possible drug or
gene therapy applications. Second, the observed increase in ath-
erosclerosis is explained by measurements indicating that the
overexpressed eNOS enzyme is dysfunctional in the mouse model
used by Ozaki et al. This finding is not unexpected, given the
moderate level of overexpression in their mice, because it has
been previously reported that endogenous eNOS is indeed dys-
functional in terms of NO production in apoE0 mice fed a West-
ern type diet (45). The results from the Ozaki et al. study are
probably (at least in part) explained by the construct used, which
consists of cDNA (often leading to low expression levels) and a
heterologous promoter. In contrast, our results demonstrate that
overexpression of human eNOS in endothelial cells indeed re-
sults in decreased atherosclerosis, most likely via lowering blood
pressure and plasma cholesterol. Our study therefore suggests
that elevation of eNOS activity could be beneficial for patients at
risk of developing atherosclerotic disease.
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